• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Evotec SE

    11/14/25 6:30:37 PM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EVO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    Evotec SE

    (Name of Issuer)


    Ordinary Shares, no par value per share

    (Title of Class of Securities)


    30050E105

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    30050E105


    1Names of Reporting Persons

    Novo Holdings A/S
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DENMARK
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    9,407,883.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    9,407,883.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    9,407,883.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.3 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Evotec SE
    (b)Address of issuer's principal executive offices:

    Essener Bogen 7, Hamburg, 2M, 22419.
    Item 2. 
    (a)Name of person filing:

    Novo Holdings A/S, a Danish corporation, is an investment firm focused on life sciences and finance that is wholly owned by Novo Nordisk Foundation (the "Foundation"), a Danish commercial foundation. Novo Holdings A/S is the holding company in the group of Novo companies, currently comprised of Novo Nordisk A/S and Novozymes A/S (also known as Novonesis A/S), and is responsible for managing the Foundation's assets, including its financial assets. Based on the governance structure of Novo Holdings A/S and the Foundation, the Foundation is not deemed to have any beneficial ownership of the securities of the Issuer held by Novo Holdings A/S.
    (b)Address or principal business office or, if none, residence:

    Tuborg Havnevej 19 2900 Hellerup, Denmark
    (c)Citizenship:

    Denmark
    (d)Title of class of securities:

    Ordinary Shares, no par value per share
    (e)CUSIP No.:

    30050E105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    9,407,883
    (b)Percent of class:

    5.3%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    9,407,883

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    9,407,883

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Novo Holdings A/S
     
    Signature:Barbara Fiorini
    Name/Title:Barbara Fiorini, General Counsel, Finance & Operations
    Date:11/14/2025
    Get the next $EVO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EVO

    DatePrice TargetRatingAnalyst
    4/24/2025Sell → Hold
    Deutsche Bank
    10/7/2024Buy → Hold
    Jefferies
    8/8/2024Hold → Sell
    Deutsche Bank
    7/29/2024$15.00 → $6.00Overweight → Equal-Weight
    Morgan Stanley
    7/11/2024Buy → Hold
    Deutsche Bank
    4/12/2024Hold → Buy
    Deutsche Bank
    1/18/2024Sector Perform → Outperform
    RBC Capital Mkts
    6/23/2023$12.00 → $16.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $EVO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Evotec SE

    SCHEDULE 13G/A - Evotec SE (0001412558) (Subject)

    11/14/25 6:30:37 PM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Evotec SE

    6-K - Evotec SE (0001412558) (Filer)

    11/6/25 11:02:58 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Evotec SE

    6-K - Evotec SE (0001412558) (Filer)

    11/5/25 6:01:38 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases

    Yonsei University, Zymedi and Evotec receive US$ 4.5m grant from the Korea Institute of Advanced Technology under the Korean Ministry for Trade, Industry and EnergyFunding supports a novel collaboration to develop first-in-class therapeutic antibodies to treat asthma and idiopathic pulmonary fibrosis HAMBURG, GERMANY / ACCESS Newswire / January 22, 2025 / Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, TRQX:EVTd, NASDAQ:EVO) announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a US$ 4.5m grant from the Korea Institute of Advanced Technology (KIAT). The KIAT grant will fund the development of first-in-class biologic therapies to treat l

    1/22/25 2:00:00 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk

    Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseasesLAB eN² is also expanding, adding Boston Children's Hospital, Boston University, Johns Hopkins University, Joslin Diabetes Center, and the Icahn School of Medicine at Mount Sinai as new participating institutions HAMBURG, DE / ACCESSWIRE / December 11, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((SDAX/TecDAX, TRQX:EVTd)(NASDAQ:EVO) announced that its translational drug discovery accelerator with Novo Nordisk, LAB eN², which aims to nurture early research from acade

    12/11/24 2:00:00 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evotec Announces Change in Management Board

    Dr Craig Johnstone steps down as Chief OperatingOfficer effective 31 December 2024Distribution of responsibilities internally HAMBURG, GERMANY / ACCESSWIRE / November 29, 2024 / Evotec SE ((Frankfurt Stock Exchange: EVT, SDAX/TecDAX, TRQX:EVTd, NASDAQ:EVO) today announced that its Chief Operating Officer, Dr Craig Johnstone, will step down and leave the Company effective 31 December 2024. Dr Johnstone joined Evotec in May 2012 as SVP Drug Discovery and Innovation Efficiency and in April 2015 was named President and Site Head, Evotec (France) SAS. Dr. Johnstone was appointed Global Head, Integrated Drug Discovery in January 2017 and became Chief Operating Officer and a member of the Managemen

    11/29/24 2:00:00 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evotec SE upgraded by Deutsche Bank

    Deutsche Bank upgraded Evotec SE from Sell to Hold

    4/24/25 7:18:16 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evotec SE downgraded by Jefferies

    Jefferies downgraded Evotec SE from Buy to Hold

    10/7/24 7:52:16 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evotec SE downgraded by Deutsche Bank

    Deutsche Bank downgraded Evotec SE from Hold to Sell

    8/8/24 8:58:18 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVO
    Financials

    Live finance-specific insights

    View All

    Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions

    Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditionsRobust growth of Just - Evotec Biologics driven by roll out of projects together with Sandoz and progress of discovery partnershipsSuccessful extensions & expansions with BMS and Novo Nordisk; new collaboration with Pfizer to advance cutting-edge therapeutic solutionsPriority reset on track to deliver annualised adj. EBITDA improvement of over € 40 m and strategic review initiated HAMBURG, GERMANY / ACCESSWIRE / November 6, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, TRQX:EVTd)(NASDAQ:EVO) today announced its financial results and corporate upda

    11/6/24 1:20:00 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evotec SE to Announce Results for the First Nine Months 2024 on 06 November 2024

    HAMBURG, GERMANY / ACCESSWIRE / October 30, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, TRQX:EVTd)(NASDAQ:EVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024.The Company is going to hold a conference call to discuss 9-months results as well as to provide an overview on the ongoing priority reset and the strategic review process. The conference call will be held in English.Webcast detailsDate: Wednesday, 06 November 2024Time: 2.00 pm CET (01.00 pm GMT, 08.00 am EST)To join the audio webcast and to access the presentation slides, please register via this link.The on-demand version of the webcast will be available on our we

    10/30/24 3:30:00 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evotec SE Reports H1 2024 Results: Challenging Year; Priority Reset for Sustainable Profitable Growth Gaining Momentum, Building on Core Strengths

    Softness in market for Shared R&D Services, with H1 2024 revenues down 7% year-on-year. Continued growth of sales order book in Discovery - higher share of integrated long-term deals will improve revenue contribution beyond 2024Strong progress of Just - Evotec Biologics with H1 2024 revenues increase of 50% year-on-year; capacity ramp-up for J.POD in Toulouse has been acceleratedChallenging market environment and high fixed cost base led to weaker profitability. Priority reset towards profitable growth gaining momentumDr Christian Wojczewski, CEO as of 1 July, is announcing an accelerated transformation programme for the company, building on the core innovation strengths of Evotec HAMBURG, G

    8/14/24 1:30:00 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVO
    Leadership Updates

    Live Leadership Updates

    View All

    Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies

    Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / September 26, 2024 / Evotec SE ((Frankfurt Stock Exchange:EVT, SDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) announced today that Evotec has entered a technology development partnership with Novo Nordisk in cell therapy.Both Evotec and Novo Nordisk have significant expertise and a strategic focus to support stem cell-based therapies. In order to provide next-generation off-the-shelf cell therapy products for clinical development and possible commercialisation thereafter, the companies will collaborate on developm

    9/26/24 2:00:00 AM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evotec SE: Results of the Annual General Meeting 2024

    Most agenda items adopted with great majorityAnnual General Meeting 2024 elects Dr Duncan McHale and Wesley Wheeler to the Supervisory Board, replacing Dr Elaine Sullivan and Dr Mario PolywkaHAMBURG, GERMANY / ACCESSWIRE / June 10, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, OTC:EVOTF)(NASDAQ:EVO) today announced that its shareholders approved most of the proposals the Company's Management put to vote at the Company's Annual General Meeting 2024 with great majority.Under the topic "Together for Medicines that Matter - Weg zum Neustart", the Chairperson of the Supervisory Board of Evotec SE, Prof. Dr Iris Löw-Friedrich, Chief Business Officer Dr Matthias Evers and Chief Fina

    6/10/24 12:15:00 PM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer

    HAMBURG, GERMANY / ACCESSWIRE / April 23, 2024 / The Supervisory Board of Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) has appointed Dr Christian Wojczewski as the Company's new Chief Executive Officer ("CEO"), effective 01 July 2024. The election was unanimous and is the result of an extensive selection process that began in January.Dr Mario Polywka, who has led Evotec as Interim CEO since 03 January 2024, will retire from his position at the end of June and will also not seek re-election for his dormant Supervisory Board mandate, which expires with the 2024 Annual General Meeting.Dr Christian Wojczewski holds a degree in chemistry and has over 20 years of

    4/23/24 3:00:00 PM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Evotec SE

    SC 13D - Evotec SE (0001412558) (Subject)

    11/8/24 9:43:55 PM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Evotec SE (Amendment)

    SC 13G/A - Evotec SE (0001412558) (Subject)

    2/14/24 4:55:09 PM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Evotec SE (Amendment)

    SC 13G/A - Evotec SE (0001412558) (Subject)

    2/2/23 1:24:31 PM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care